FACE: The barefaced facts of AI potency

Cancer Management and Research

Volumn 2, Issue 1, 2010, Pages 267-276

  Monnier, Alain ^a  

^a Centre Hospitalier Belfort Montbéliard   (France)

Author keywords

Anastrozole; Aromatase inhibitors; Hormone receptor positive (HR+) breast cancer; Letrozole; Postmenopausal women; Tamoxifen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; FADROZOLE; HORMONE RECEPTOR; LETROZOLE; PLACEBO; TAMOXIFEN;

ADJUVANT THERAPY; ADRENAL INSUFFICIENCY; ARTHRALGIA; ARTICLE; BLOOD DYSCRASIA; BREAST CANCER; CANCER HORMONE THERAPY; DISEASE FREE SURVIVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENCY; DRUG SUBSTITUTION; ENZYME INHIBITION; FOLLOW UP; GYNECOLOGIC DISEASE; HUMAN; LYMPH NODE METASTASIS; METASTASIS; NAUSEA; OSTEOLYSIS; OVERALL SURVIVAL; RECURRENCE RISK; RISK REDUCTION; SIDE EFFECT; SOMNOLENCE; THROMBOEMBOLISM;

EID: 79251481895     PISSN: None     EISSN: 11791322     Source Type: Book Series    
DOI: 10.2147/CMR.S13511     Document Type: Article

References (40)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1717.
2. Fisher B, Costantino J P, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
3. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col N F. Meta-analysis of vascular and neoplastic events associated with tamox-ifen. J Gen Intern Med. 2003;18:937-947.
4. Mouridsen HT, Bhatnagar AS. Letrozole in the treatment of breast cancer. Expert Opin Pharmacother. 2005;6:1389-1399.
5. Rieber AG, Theriault RL. Aromatase inhibitors in postmenopausal breast cancer patients. J Natl Compr Canc Netw. 2005;3:309-314.
6. Geisler J, Lonning PE. Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res. 2005;11:2809-2821.
7. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group; Forbes J F, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45-53.
8. Howell A, Cuzick J, Baum M, et al; ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365:60-62.
9. Breast International Group (BIG) 1-98 Collaborative Group; Thürli-mann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747-2757.
10. Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25:486-492.
11. BIG 1-98 Collaborative Group; Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361: 766-776.
12. Thurlimann B; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Letrozole versus tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. 39th St. Gallen Symposium; 2009 May 7-9; St. Gallen, Switzerland. Abstr 0161.
13. Coombes RC, Kilburn LS, Snowdon CF, et al; Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369:559-570.
14. Goss, PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated fndings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262-1271.
15. Geisler J, Helle H, Ekse D, et al. Letrozole is superior to anastrozole suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer Res. 2008;14:6330-6335.
16. Dixon JM, Renshaw L, Young O, et al. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol. 2008;26: 1671-1676.
17. Baum M, Buzdar AU, Cuzick J, et al; for the ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: frst results of the ATAC randomized trial. Lancet. 2002;359:2131-2139. Erratum in: Lancet. 2002;360:1520.
18. Arimidex [package insert]. Wilmington, DE: AstraZeneca; Rev. 12/08.
19. McArthur HL, Olivotto I, Gelmon KA, et al. Risk of early relapse in post-menopausal women with early stage, estrogen receptor positive (ER+) breast cancer on tamoxifen. Breast Cancer Res Treat. 2005; 94 Suppl 1:S124. Abstr 3001.
20. Hortobagyi GN, Kau S-W, Buzdar AU, et al. What is the prognosis of patients with operable breast cancer (BC) fve years after diagnosis? Proc Am Soc Clin Oncol. 2004;23:23. Abstr 585.
21. Buzdar AU, Guastalla J P, Nabholtz JM, Cuzick J; ATAC Trialists' Group. Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial. Cancer. 2006;107:472-480.
22. Lamerato L, Havstad S, Gandhi S, Jones D, Chlebowski R. Breast cancer recurrence and related mortality in US pts with early breast cancer. J Clin Oncol. 2005;23(16S):62s. Abstr 738.
23. Doughty JC, Mansell J, Monypenny I, et al. Distant recurrence and subsequent mortality in breast cancer patients treated at 5 UK centres. 39th St. Gallen Symposium; 2009 May 7-9; St. Gallen, Switzerland. Abstr 0188.
24. Vakaet L, Buyse M. Comparative results of two adjuvant trials comparing 5 years of an aromatase inhibitor (AI) with 5 years of tamoxifen (TAM) in postmenopausal women with early breast cancer (EBC). Breast Cancer Res Treat. 2006;100 Suppl 1:S108-S109. Abstr 2084.
25. Mauriac L, Keshaviah A, Debled M, et al; BIG 1-98 Collaborative Group; International Breast Cancer Study Group. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol. 2007;18:859-867.
26. Gligorov J, Azria D, Pivot X, Penault-Llorca F, Spielmann M, Namer M. Clinical impact of upfront adjuvant AI therapy on the early risk of recurrence. Eur J Cancer. 2007;5(Suppl):209. Abstr 2089.
27. Houghton J, on behalf of the ATAC Trialists' Group. Initial adjuvant therapy with anastrozole (S) reduced rates of early breast cancer recurrent and adverse events compared with tamoxifen (T) - data reported on behalf of the ATAC ('Arimidex', TAM, Alone or in Combination) Trialists' group. Ann Oncol. 2006;17 Suppl 9:ix93. Abstr 243PD.
28. Howell A, Forbes J, Cuzick J. Initial adjuvant therapy with anastrozole - early and late event data from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial in the hormone-responsive population. 39th St. Gallen Symposium; 2009 May 7-9; St. Gallen, Switzerland. Abstr 0130.
29. Rugo H, Rourke M, Dranitsaris G, Kaura S. Letrozole or anastrozole for the prevention of early recurrences in postmenopausal women with early stage breast cancer: Using number needed to treat (NNT) to compare beneft. Eur J Cancer Suppl. 2008;6:118. Abstr 236.
30. Mansell J, Monypenny IJ, Skene AI, et al. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat. 2009;117: 91-98.
31. Rugo HS, Kaura S, Dranitsaris G. The number needed to treat to save a life: a comparison between aromatase inhibitors. 39th St. Gallen Symposium; 2009 May 7-9; St. Gallen, Switzerland. Poster 136.
32. Dhillon N, Kaura S, Dranitsaris G, Rugo H. Number needed to treat (NNT) to compare benefts of letrozole (LET) with adjuvant chemotherapy (CT) in patients (pts) with node-positive (N+) breast cancer (BC). J Clin Oncol. 2009;27:15s. Abstr 581.
33. Gershanovich M, Chaudri HA, Campos D, et al. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol. 1998;9:639-645.
34. Rose C, Vtoraya O, Pluzanska A, et al. An open randomized trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer. 2003;39:2318-2327.
35. Dowsett M, Jones A, Johnston SR, Jacobs S, Trunet P, Smith IE. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res. 1995;1:1511-1515.
36. MacNeill FA, Jones AL, Jacobs S, Lønning PE, Powles TJ, Dowsett M. The infuence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer. 1992;66: 692-697.
37. Furet P, Batzl C, Bhatnagar A, Francotte E, Rihs G, Lang M. Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds. J Med Chem. 1993;36:1393-1400.
38. Monnier A. Refning the postmenopausal breast cancer treatment paradigm: the FACE trial. Expert Rev Anticancer Ther. 2006;6: 1355-1359.
39. de Boer R Sr, Burris HA, Monnier A, et al; on behalf of the H2H trial steering committee. The Head to Head trial: Letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer. J Clin Oncol. 2006;24(18s):582s. Abstr 10672.
40. NCIC Clinical Trials Group. Exemestane or anastrozole in treating postmenopausal women who have undergone surgery for primary breast cancer. http://clinicaltrials.gov/ct2/show/NCT00066573. Accessed 2010 Jun 7.